Although people who recover from COVID-19 usually gain some immune defenses against reinfection, they get additional protection from vaccines, especially against severe disease, according to two studies published on March 31 in The Lancet Infectious Diseases. Additionally, two gold-standard trials published in The New England Journal of Medicine on March 30 help settle questions about two controversial therapies touted by many early in the pandemic with decidedly mixed results – failure for the antiparasite drug ivermectin and success for antibody-rich blood plasma from COVID-19 survivors.

Another study is adding to a growing body of literature that suggests convalescent plasma from recovered patients with Covid-19 does not prevent further Covid-19 progression in at-risk people who visit the emergency room.

The U.S. National Institutes of Health (NIH) halted a trial of convalescent blood plasma in the treatment of patients with mild-to-moderate Covid-19 symptoms as it was unlikely to benefit this group.

A study published in JAMA suggests that treatment with vitamin C, in addition to thiamine and hydrocortisone, does not improve treatment outcomes in hospitalized patients with sepsis.

A study showed the use of convalescent plasma provided no clinical benefit nor improved mortality in Covid-19 patients with pneumonia.

Using blood plasma from Covid-19 survivors to treat patients with severe pneumonia caused by the novel coronavirus showed little benefit, according to data released from a clinical trial in Argentina.

The U.S. government will start distributing Regeneron Pharmaceuticals Inc.’s newly authorized Covid-19 antibody combination on Nov. 24, beginning with more than 30,000 treatment courses, a health official said.

Researchers called for more research into using blood from recovered Covid-19 patients – or so-called convalescent plasma – as a potential treatment, after a small trial of hospitalized patients in India found it was of no benefit.

A roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines includes a higher complication rate with Covid-19 versus the flu.

White House Reverses Course, Approves New FDA COVID-19 Vaccine Guidelines Published: Oct. 7, 2020 By Alex Keown BioSpace   The White House has reversed its position on new vaccine guidelines proposed by the U.S. Food and Drug Administration. The approval of the new guidelines all but assures that a vaccine for the novel coronavirus that has […]